About faricimab
Bispecific VEGF-A and Ang-2 inhibitor
Used for
- Neovascular (wet) age-related macular degeneration
- Diabetic macular edema
- Macular edema following retinal vein occlusion
Usual adult dose
6 mg injected into the eye every four weeks initially; intervals may be extended based on response and condition.
Common side effects
- Cataract
- Conjunctival bleeding
- Eye pain or irritation
- Increased eye pressure
Important warnings
- Eye injections can cause infection, retinal detachment, or serious inflammation.
- Seek urgent assessment for sudden vision changes or worsening eye pain.
- Avoid use during active eye or nearby infections.
- May increase risk of arterial blood clots.
Pregnancy
Potential fetal risk; pregnancy data are limited. Effective contraception is recommended during treatment and for three months after the last dose.
Breastfeeding
Unknown whether faricimab passes into breast milk; effects on the infant are uncertain.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.